Cancer Seminar Series

Join us for this interdisciplinary seminar series highlighting cutting edge clinical, translational, and basic research topics in cancer from our research partner institutes: UQ Diamantina, QUT and the Mater. Focussing primarily on communicating the findings of early-to-mid career researchers, new faculty members along with notable guest speakers, this seminar series serves as an important tool to promote discussion and collaboration.

Key Researchers
  • Dr Jatin Patel
  • Dr Jenni Gunter
  • Dr Mark Adams
  • Dr Yaowu He

Key Aims
  • Promote researchers
  • Encourage discussion 
  • Enable collaboration
  • Share techniques

 
Seminar Details Speaker Title Speaker Bio

Date: Thursday 29 October

Time: 9am - 10am

Zoom ID: 83560212942

Dr Patrick Thomas (QBCI and QUT) and Dr Laura Genovesi (UQDI)

"Initiation of a Precision Medicine Program in Bladder Cancer Utilizing Bladder Cancer Organoids" Presented by Dr Patrick Thomas (QBCI and QUT)

"Systems pharmacogenomics identified novel targets and clinically actionable therapeutics for Medulloblastoma" Presented by Dr Laura Genovesi (UQDI)

Initiation of a Precision Medicine Program in Bladder Cancer Utilizing Bladder Cancer Organoids
Bio: Dr Patrick Thomas is a Postdoctoral Research Fellow in the Queensland Bladder Cancer Initiative (QBCI) and part-time academic in the School of Biomedical Sciences, QUT. Dr Thomas’ research focuses directly on patient-derived tumour models, immuno-oncology, microbiology and genomics in urological cancers - with the aim to develop personalised prediction models for therapy response. Dr Thomas is a team member of the Australian Prostate Cancer Research Centre (APCRC-Q), a proud 9-year Movember veteran and board member of Prostate Awareness Australia (PAA).
 

Dr Laura Genovesi is a Cure Brain Cancer Early Career Research Fellow in the Paediatric Brain Tumour group at UQDI.  Dr Genovesi was awarded her PhD in 2012  from the University of Western Australia and relocated to the Institute for Molecular Bioscience (IMB) at the University of Queensland to commence her post-doctoral studies in the laboratory of Prof. Brandon Wainwright.  Dr Genovesi's post-doctoral research focuses on characterising and targeting the genetic networks driving medulloblastoma growth. Dr Genovesi uses diverse model systems, including patient derived xenografts and genetically engineered mouse models,  to explore both basic tumour biology and response to therapy.  Her work has contributed to the therapeutic application of CDK4/6 inhibitors in the treatment of medulloblastoma, forming the basis of an international clinical trial.

Date: Thursday 15 October

Time: 9am - 10am

Zoom ID: 83560212942

Dr Nathalie Bock or Dr Yaowu He

"A microtissue-engineered osteoblastic model reveals the effects of anti-androgen therapies in the bone tumor microenvironment of prostate cancer" Presented by Dr Nathalie Bock

“Blocking aurora kinase B improves the efficacies of chemotherapies for ovarian cancer” Presented by Dr Yaowu He

Dr Nathalie Bock is a Senior Research Fellow and Deputy Director of the Regenerative Medicine Program at QUT. Her research is about developing biomimetic 3D cell culture model systems using advanced biomaterials and tissue engineering technologies, to study bone biology and bone metastases. One of the research goals in Dr Bock’s lab includes the development of in vitro preclinical models for personalised drug testing in prostate and breast cancer. Dr Bock has expertise in controlled drug delivery, biofabrication, hydrogels and fibre-based scaffolds, bone tissue engineering, 4D imaging and bone cancer biology.

Date: Thursday 1 October

Time: 9am - 10am

Zoom ID: 83560212942

Dr Camille Guillerey and Dr Seth Cheetham

"Developing new tools to investigate Natural Killer cell responses to Childhood Leukaemia" Presented by Dr Camille Guillerey

"Nanopore sequencing enables comprehensive profiling of transposable element insertions and epigenetic states in cancer" Presented by Dr Seth Cheetham

Dr Camille Guillerey is a Senior Research Officer in the Cancer Immunotherapies Group at Mater Research. She leads a small team of 3 researchers and students.
Through her first postdoc at QIMR Berghofer, Camille has made integral contributions to improve knowledge on immune responses to blood cancers. She identified the immune molecules TIGIT and CD137 as promising targets in immune multiple myeloma, an incurable blood cancer. Camille joined A/Prof Kristen Radford’s group in late 2018. Camille’s research is currently focused on Natural Killer cells, a population of immune cells that recognise and kill cancer cells. She aims to identify mechanisms that may prevent Natural Killer cells from eliminating cancer cells and apply these findings to develop new treatments for childhood leukemia.
 

Dr Seth Cheetham is an NHMRC Early Career Fellow in Professor Geoffrey Faulkner’s Group at Mater Research Institute-UQ. Seth conducted his Honours project with Professor John Mattick at the Institute for Molecular Bioscience at UQ, focussed on differentiating human protein-coding and noncoding RNA transcripts. For his PhD, he joined the group of Professor Andrea Brand at the University of Cambridge to study the functions of long noncoding RNAs (lncRNAs) in neural development and the mechanisms through which they act. Dr Cheetham’s current research focuses on deciphering the functions of repetitive elements in cancer using novel tools including third generation sequencing platforms and DamID-based approaches.  

Date: Thursday 3 September

Time: 9am - 10am

Zoom ID: 83560212942

Dr Arun Everest-Dass and A/Prof Daniel Kolarich

"Painting Sweet Pictures: Glycomics using Mass Spectrometry" presented by Dr Arun Everest Dass

"Deciphering the Glyco-Language of Diseases" presented by A/Prof Daniel Kolarich

Dr Arun Everest-Dass is a Research Fellow at the Institute for Glycomics (Griffith University). He is the mass-spectrometry imaging lead at the Institute and is developing novel techniques to image and map glycans from tissues and cells. Dr Everest-Dass is furthering this field of study through the development of novel mass-spectrometry methods for glycomics, proteomics, and glycoproteomics. In his presentation, he will show several examples demonstrating the application of imaging mass spectrometry to study cellular glycosylation changes in diseases, such as cancer, in sub-typing and delineation of highly heterogeneous tissues.

Dr Daniel Kolarich is a research leader at the Institute for Glycomics (Griffith University). He was awarded an ARC future fellowship in late 2016 and joined the Institute for Glycomics at Griffith University in January 2017 continuing his research in disease and evolutionary glycomics and glycoproteomics. In his presentation, he will present the latest technical advances how glycan can be sequenced, and how this information can be used to better understand molecular interactions and disease pathogenesis.

Date: Thursday 20 August

Time: 9am - 10am

Zoom ID: 83560212942

Mitchell Stark and Mark Adams 

“Mutational signatures in benign neoplasms of the skin”presented by Mitchell Stark 

"Enhancing chemotherapy response in non-small cell lung cancers" presented by Mark Adams

Dr Stark is currently a University of Queensland (UQ) Amplify Research Fellow based in the Dermatology Research Centre, at The UQ Diamantina Institute. He was awarded his PhD in 2015 and has been actively working in the field of melanoma and naevi genomics and biomarker development for 20+ years. Prior to relocating to UQ, he was trained and mentored at the QIMR Berghofer Medical Research Institute (1999-2015). Over this time Dr Stark has been working towards understanding the aetiology of melanoma, studying gene dysregulation during tumour progression along with predisposition to melanoma in families with high risk for melanoma development. His teams primary research focus is identifying early signs of melanoma progression via ‘melanoma-specific’ microRNAs as well as genomic profiling of precursor skin lesions that may be useful for clinical management of disease. He is the author of 68 scientific publications and one patent (h-index, 34).

Mark Adams is currently a Strategic Research Fellow at the Institute of Health and Biomedical Innovation-Queensland University of Technology (QUT). He completed his PhD at the Mater Research Institute-University of Queensland in 2012 and with the support of an NHMRC Fellowship commenced postdoctoral work at QUT. Dr Adams now leads a team within the Cancer and Ageing Research Program (CARP) at TRI. His research focuses on exploiting genome instability and cell cycle control to identify novel therapeutic avenues and improve chemotherapy response. Dr Adams is currently supported by QUT, the International Lung Cancer Foundation and Cure Cancer Australia.

Date: Thursday 6 August

Time: 9am - 10am

Zoom ID: 83560212942

Prof Maher Gandhi  "The Molecular Landscape of Virally Driven Brain Lymphomas: An Opportunity for Targeted Therapies" 

Professor Maher Gandhi is the Executive Director of Mater Research, a practising haematologist at Princess Alexandra Hospital and former Leukaemia Foundation Chair of Blood Cancer Research at UQ.
His research interest is the immunobiology of lymphoma, with a strong emphasis on translational patient-orientated biomedical research.

He will present his most recent data, in which he led a large international consortium to provide the first large-scale characterisation of an extremely rare and hitherto un-investigated sub-type of a highly aggressive lymphoma. His results led the development of a novel treatment regimen that is currently in undergoing a world-first Australia-wide clinical trial.

Date: Thursday 9 July

Time: 9am - 10am

Zoom ID: 83560212942

A/Prof Theresa Hickey  "Androgen receptor signalling trans-repressses estrogen receptor signalling in breast cancer"

Associate Professor Theresa Hickey is the Scientific Program Leader of the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL), Adelaide Medical School, University of Adelaide and a current National Breast Cancer Foundation Research (NCBF) Fellow.

She is internationally recognised for her research on sex hormone action in female reproductive tissues and disorders, with specific expertise in breast cancer. Theresa has pioneered new treatment strategies for breast cancer and established a patient-derived ex vivo culture methodology as a powerful new pre-clinical tool for drug development. Her group’s innovative work in this area has attracted substantial national and international interest in using the ex vivo culture technique as a pre-clinical model in several different tumour types.

Date: Thursday 11 June

Time: 9am - 10am

Zoom ID: 834 0347 4071

Dr Laura Sormani and Dr Honor Hugo

"CLEC12B : a new player in skin pigmentation and melanoma" presented by Dr Laura Sormani 

"Heparanase promotes Syndecan-1 expression to mediate fibrillar collagen and mammographic density in human breast tissue cultured ex vivo" presented by Dr Honor Hugo

Dr Laura Sormani is a research officer post-doctoral fellow interested in the biology of melanoma genesis and progression. She completed her PhD in 2019 at the Mediterranean Centre for Molecular Medicine (C3M, Côte d’Azur University, Nice, France) under the supervision of Professor Thierry Passeron, a world leading expert in skin pigmentation.  During her PhD she discovered, patented and characterized a novel pigmentation gene CLEC12B demonstrating a key role not only in skin pigmentation but also in melanonagenesis, thereby exerting functions beyond immunity and inflammation. Dr Laura Sormani has recently joined the lab of Professor Kiarash Khosrotehrani at the University of Queensland Diamantina Institute as a postdoctoral fellow to work on the molecular pathways involved in melanoma vascularisation.

Dr Honor Hugo (PhD) joined the School of Biomedical Science, Faculty of Health, Queensland University of Technology as a Research Officer and Lecturer in 2016 . As an award winning researcher, Dr Hugo and a team of scientists at QUT, who have active and ongoing connections with industry aim to develop alternate ways of detecting breast density without exposing women to ionizing radiation, as occurs in mammography. The other component of her research focuses on understanding the underlying biological mechanism through which mammographically dense breast tissue increases the risk of developing breast cancer, employing a unique mammary tissue explant approach. Her recent publication defines the use of single-sided NMR technology to determine mammographic density change in this explant model, a world first in this field of research. 

Cancelled

Date: Thursday 19 March

Time: 9am-10am

Venue: Seminar Room 2003

A/Prof Fiona Simpson  Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

Fiona Simpson leads her cancer research team in the University of Queensland Diamantina Institute and has been working for last 10 years analysing patient and immune responses to monoclonal antibody therapies. Her research program brings together Clinicians, Chemists, Pathologists, cell biologists and immunologists and emphasises the translation of research findings into therapies.  Today she will be discussing her recent high impact manuscript published in Cell.

Date: Thursday 5 March

Seminar: 9am-10am

Venue: Seminar Room 2003

Professor John Hooper (Mater Research Institute) Standing on the outside looking in - models and molecular targets for advanced ovarian and pancreactic cancer

John Hooper leads the Cancer Biology Laboratory at the Mater Research Institute UQ. His research focus is on cancers of the ovary, pancreas, prostate and bowel, studying the molecular drivers of these malignancies and pre-clinical testing of new diagnostic/predictive tools and drug leads. His laboratory works closely with clinical teams involved in the care of cancer patients, and with companies engaged in the translation of biomedical discoveries for clinical use.

Date: Thursday 5 March

Seminar: 9am-10am

Venue: Seminar Room 2003

Dr. Brittney Harrington (NIH, Maryland)

Drugs targeting ovarian cancer tumour-initiating cells enhance oxidative stress and prevent disease recurrence

Dr. Brittney Harrington is a Postdoctoral Fellow performing translational research at the National Cancer Institute of the National Institutes of Health in Maryland, USA. Dr. Harrington completed her undergraduate and postgraduate studies at the University of Queensland, and Mater Research Institute in Brisbane, Australia. Dr. Harrington's research is focused on the discovery of new targeted therapies for ovarian cancer and using clinically relevant models of the disease. 

Date: Tuesday 20 February 

Seminar: 9am-10am

Venue: Seminar Room 2003

Dr Pascal Dujf Chromosome arm aneuploidies shape tumour evolution and drug response

Dr Pascal Duijf obtained a Bachelor's degree in Biology and a Master's degree in Medical Biology from the Radboud University Nijmegen in the Netherlands and was awarded two scholarships that enabled him to gain research experience in cell biology at Harvard Medical School in Boston, MA in the United States. His research focuses on identifying the causes and consequences of genomic instability in the development of cancer (see also 'Research Interests' below for more details). He aims to translate this knowledge into the development of cancer diagnostic, therapeutic and precision medicine approaches. To achieve this, he uses a broad range of methods, including mouse modelling, genome editing, microscopy, cell and molecular biology, molecular pathology, proteomics and computational systems genomics.

 

2018 SCHEDULE

Date Speakers Title
22/02/2018 Dr. Jatin Patel (UQDI) Endovascular progenitors initiate and drive de novo vascularisation in melanoma
Dr. Nathalie Bock (QUT) An in vitro bioengineered bone model to study the effects of androgen deprivation in the bone metastatic microenvironment of prostate cancer
08/03/2018 TBC TBC
Abdullah Al Emran (Dermatology Research Centre, UQDI) Commonly integrated epigenetic modifications of differentially expressed genes lead to acquired drug resistance in cancer
22/08/2018 Cancelled
05/04/2018 Prof. Amanda Spurdle (QIMR) Clinical classification of genetic variants: Research informing practice
19/04/2018 Prof. Nikolas Haass (UQDI) RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes
Farhana Matin (QUT) A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer
03/05/2018 Dr. Chris Slape (UQDI) EphA3: A new kind of oncogene
Dr. Mitchell Stark (Dermatology Research Centre, UQDI) Whole exome analysis of naevi reveals mechanisms for development and maintenance of benign neoplasms
17/05/2018 Dr. Rehan Villani (UQDI) Deciphering the role of cancer-associated fibroblasts in basal cell carcinoma
Arutha Kulasinghe (QUT) Circulating tumour cells: the "leukemic" phase of solid cancers
31/05/2018    
Dr. Dubravka Skalamera (MRI) Using high-content time-lapse imaging to investigate effects of oncogenic mutations in melanocyte-keratinocyte-fibroblast interaction
14/06/2018 Dr. Abu Sina (AIBN, UQ) Interfacial Biosensing: A new avenue for sensing cancer biomarkers
28/06/2018 Dr. Kelly-Anne Masterman (MRI) Harnessing CD141+ Dendritic Cells (DC) for immunotherapy
   
12/07/2018 Dr. Tracy O'Mara (QIMR) TBC
26/07/2018 Cancelled due to TRI symposium
09/08/2018 Prof. Glen Boyle (QIMR) (TRI auditorium) Yin and Yang: Consequences of heterogeneous transcription factor expression in melanoma
23/08/2018 Dr. Samantha Stehbens (UQDI) Microtubule-Dependent Mechanosensing in Cell Migration and Cancer Invasion
   
06/09/2018 Dr. Julia Pagan (UQ School of Biomed. Sc.) Regulation of cellular pathways by SCF ubiquitin ligases
20/09/2018 Dr. Roberta Mazzieri Resetting the Tumour Microenvironment to Improve cancer Immunotherapy
Dr Jay Gunawardana Somatic IL4R Mutations in Primary Mediastinal B-cell Lymphoma
04/10/2018 Dr. Daniel Kerage (UQDI) TBC
   
18/10/2018 Dr. Shannon Joseph (UQDI) EGFR trafficking distribution, therapeutic outcomes and therapeutic potential
Heinz Hammerlindl (Dermatology Research Centre, UQDI) Characterisation of therapy induced cellular reprogramming identifies vulnerabilities during the development of drug resistance in BRAF mutant melanoma
15/11/2018 Joachim Torrano (Dermatology Research Centre, UQDI) The potential role of IFN-mediated H3K9me3 in therapy-induced reprogramming
Martin Sadowski (QUT) Lipid uptake fuels the fury of prostate cancer
     
29/11/2018   TBC
 

 

 

2017 SCHEDULE ARCHIVE

Date Speakers Topic
09/03/2017 Dr. Yaowu He (Mater) Functional importance of CDCP1 in colorectal cancer
Dr. Jatin Patel (UQDI) Defining the vascular stem cell niche for cancer and tissue regeneration
23/03/2017 Dr. Orla Gannon (UQDI) Are pathogens associated with breast cancer?
Phoebe Sarkar (APCRC-Q) Characterizing the role of insulin in advanced prostate cancer
06/04/2017 Dr. Pascal Duijf (UQDI) Pan-cancer analysis identifies novel features of chromosome arm-level somatic copy number aberrations
Chris Oh (IMB, UQ)  Epigenetic signalling of nuclear hormone receptor and cofactor in breast cancer
20/04/2017 TBC TBC
04/05/2017 Prof. Riccardo Dolcetti (UQDI) Personalized immunotherapy to overcome tumour heterogeneity
18/05/2107 Abdullah Emran (UQDI / Dermatology Research Centre) Distinct histone modifications define early drug resistance in cancer
Jana Panchadsaram (APCRC-Q) The role of 5p15 locus in prostate cancer risk and progression
01/06/2017 Dr. Kyle Upton (UQ School of Chemistry) Mobile genetic elements in epithelial cancers
15/06/2017 Dr. Samantha Stehbens (UQDI) Fibroblast Growth Factor Receptor 2 activating mutations Potentiate Migration and Invasion in Endometrial Cancer
Heinz Hammerlindl (UQDI / Dermatology Research Centre) H3K4me3 remodelling drives acquired BRAF inhibitor resistance in melanoma
29/06/2017 Kaylyn Tousignant (QUT) Enhanced lipid uptake: a novel target to fight the adaptive response to androgen-targeted therapies in prostate cancer
Thomas Keech (Mater) Bone marrow macrophages in acute myeloid leukaemia
13/07/2017 Sharon Del Vecchio (UQDI, PAH) and Dr. Aaron Urquhart (Diagnostic Imaging, TRI) Decoding the spectral fingerprint of kidney cancer
27/07/2017 Dr Honor Hugo (QUT) Insight into mammographic density from human breast tissue cultivated ex vivo
Dr Ati Taherian Fard (APCRC-Q) Temporal transcriptional dynamics of ZEB1-induced EMT in prostate cancer
10/08/2017 Dr. Andreas Moeller (Head of Tumour Microenvironment, QIMR Berghofer) Cancer-derived exosomes as new prognostic markers
24/08/2017 Dr. Stephen Mattarollo (UQDI) Neuro-immuno-metabolic interactions in the tumour microenvironment
Scott Lovell (Visiting scholar, QUT) Novel activity-based probes for the assessment of KLK activities in prostate cancer
07/09/2017 Prof. Stacey Edwards (QIMR) From GWAS to new drug targets for breast cancer
21/09/2017 Dr. Patricia Carreira Moreno (Mater) Selection of a tumour-specific L1 insertion in the STC1 gene after chemotrherapy in an ovarian cancer patient
Farzana Ahmed (UQDI) The role of MITF in melanoma tumour heterogeneity and drug resistance
05/10/2017 Dr. James Wells (UQDI) Rapamycin-induced reduction of de novo squamous cell carcinoma establishment - a role for CD8-T-cells?
   
19/10/2017 Dr. Shannon Joseph (UQDI) Reversing resistance to monoclonal antibody therapy in metastatic Head and Neck Squamous Cell Carcinoma and triple negative breast cancers - CESTEM trial update
   
02/11/2017 Prof. Shubha Chiplunkar (Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India) Gamma delta T cells and cancer immunotherapy
Rayzel Fernandes (Dame Roma Mitchell Cancer Research Labs, University of Adelaide) miR-194 regulates androgen receptor signalling in prostate cancer
16/11/2017 Dr. Abbas Shafiee (ihbi) TBC
22/11/2017 Special Cancer-Immunology seminar: International speaker Professor Tetsuo Akimoto (National Cancer Center Hospital East, Japan) Proton beam therapy: state-of-the-art technology to target cancer. Clinical outcomes and current status in Japan
30/11/2017 Dr. Loredana Spoerri (UQDI) MITF regulates dynamic heterogeneity and structural integrity in melanoma

 

2016 SCHEDULE ARCHIVE

ate Speakers Topic
14/04/2016 Dr Peter Simpson Invasive lobular carcinoma – a special type of breast cancer
28/04/2016 Dr Graham Leggat Tissue-resident memory T cells in precancerous skin
  Shiv Hiriyur Nagaraj TBC
12/05/2016 Dr Stephen Matarollo Improving response to immunotherapy in blood cancers
  Dr Daniela Loessner Engineering of tumour microenvironments
26/05/2016 Dr Mitch Starck "Melanoma-microRNAs”: from novel disease biomarkers through to target gene identification and regulation.
9/06/2016 Dr James Wells Understanding the involvement of CD8 T-cells in the control of cutaneous squamous cell carcinoma
  Dr Yonghua Sheng MUC13 Protects Colorectal Cancer Cells from Death by Activating the NF-κB Pathway and Is a Potential Therapeutic Target
23/06/2016 Dr Aaron Smith External Speaker (SBMS)  Melanoma
7/07/2016 QUT Speaker TBC
  Mater Speaker TBC
21/07/2016 Dr Jatin Patel Defining the vascular stem cell niche for cancer and tissue regeneration
4/08/2016 Dr Lynn Fink Using the MLL Fusion Transcriptome for Diagnosis in Childhood Acute Myeloid Leukaemia
  Dr Eloise Dray Exploiting DNA repair defects in breast cancer
18/08/2016 John Price External Speaker: Victoria Uni
1/09/2016 Dr Alice Kamphorst RESCUE OF EXHAUSTED CD8 T CELLS BY PD-1 TARGETED THERAPIES IS CD28-DEPENDENT
  Mater  TBC
29/09/2016 Dr Alok Shah TBC
  Thomas Kryza TBC
13/10/2016 Srividya Vaidyanathan TBC
  Vanessa Bonazzi TBC
27/10/2016 Dr Graeme Walker External Speaker (QIMR) : Melanoma
10/11/2016 TBC Mater
  TBC QUT
24/11/2016 TBC External Speaker
8/12/2016 Dr Loredana Spoerri Melanoma
  QUT  TBC